Press release
Oxipit Secures Brazilian ANVISA Clearance for ChestEye AI Suite
CEO of Oxipit Gediminas Peksys
"With many future-focused healthcare organizations, LatAm market shows tremendous potential for healthcare AI applications. Oxipit products have already shown strong market traction in the region. The ANVISA certification will solidify our presence in the Brazilian market, with new clinical deployments coming soon" - says Oxipit CEO Gediminas Peksys.
Oxipit ChestEye AI suite includes CAD, triage and quality assurance features. The product produces preliminary reports for 75 most common chest findings. The software can prioritize patient reporting workflow. The application can also act as a second reader - utilizing AI to look for findings that the radiologist might have missed in his report. Furthermore, ChestEye may be used for healthy patient report automation.
"ChestEye serves as the stepping stone for organizations to embrace AI. Starting from CAD and preliminary reports, healthcare institutions can then move to extended platform features - such as quality assurance or automation - based on their usage scenarios" - adds Gediminas Peksys.
ANVISA certification is one of Oxipit steps towards expansion into new markets. The company recently closed a $4.9M funding round with the aim to boost global Oxipit presence.
The company is gearing up towards the European Congress of Radiology in March, where the updated Oxipit Quality AI powered double reading application will be presented to the European audience for the first time. At ECR Oxipit will also showcase ChestLink autonomous AI application, presenting possible autonomous reporting workflows and feedback from initial product deployments.
At ECR Oxipit AI medical imaging products will be presented at booth AI-38.
www.oxipit.ai
Saulėtekio al. 15-1, LT-10224 Vilnius
Lithuania
ABOUT OXIPIT
Oxipit develops AI applications for diagnostic medical imaging. With a team of award-winning data scientists and medical doctors, the company aims to introduce innovative artificial intelligence breakthroughs to everyday clinical practice.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oxipit Secures Brazilian ANVISA Clearance for ChestEye AI Suite here
News-ID: 2931546 • Views: …
More Releases from Oxipit
Oxipit Partners With CARPL To Increase Global Reach Of AI Diagnostic Products
At the European Congress of Radiology in Vienna Oxipit announced that its diagnostic AI solutions will be available on the CARPL platform. CARPL platform users will have access to the full Oxipit AI product portfolio: ChestLink for healthy patient report automation, Quality - for real-time quality assurance and ChestEye - for preliminary reports. The move further builds on Oxipit strategy to increase global reach of company's products.
"CARPL is our…
Oxipit Closes $4.9M Funding Round To Advance AI Autonomy in Medical Imaging
AI medical imaging company Oxipit closed a $4.9M funding round led by Taiwania Capital and Practica Capital. Angel investors also participated in this round. The funding will help Oxipit advance its development of autonomous AI medical imaging applications and support market expansion into new geographic regions, with particular focus on the United Kingdom.
"2022 was a breakthrough year for the Oxipit team. In spring we introduced ChestLink - the first fully…
Oxipit Introduces Quality Assurance for MSK, MG, and CT Modalities
AI medical imaging company Oxipit expanded its Quality product suite with quality assurance support for musculoskeletal X-rays, mammography images and lung CT scans. Previously supporting only chest X-rays, the upgraded Quality suite aims to answer all imaging department quality assurance needs with a single product. The updated Quality product will be showcased at RSNA 2022 annual meeting later this month.
Oxipit Quality employs AI as the second reader for quality assurance.…
Kaunas city polyclinic picks ChestLink to speed up preventative health checks
Kaunas city polyclinic introduced Oxipit ChestLink AI application in their preventive health check up workflow. With ChestLink, which can automatically identify normal chest X-rays, healthy patients can be instantly sent home after the examination, without the need to wait for the study report at the polyclinic. Operating with 99.9% sensitivity, ChestLink can automatically report on 26% of all X-ray studies at Kaunas city polyclinic.
Kaunas city polyclinic performs more than 140.000…
More Releases for Gediminas
Oxipit Introduces Quality Assurance for MSK, MG, and CT Modalities
AI medical imaging company Oxipit expanded its Quality product suite with quality assurance support for musculoskeletal X-rays, mammography images and lung CT scans. Previously supporting only chest X-rays, the upgraded Quality suite aims to answer all imaging department quality assurance needs with a single product. The updated Quality product will be showcased at RSNA 2022 annual meeting later this month.
Oxipit Quality employs AI as the second reader for quality assurance.…
Oxipit Awarded CE Mark For The First Autonomous AI Medical Imaging Application
AI medical imaging application developer Oxipit was granted CE Class IIb certification for ChestLink autonomous AI imaging suite. The application autonomously reports on chest X-rays featuring no abnormalities without any involvement from a radiologist. It is the first regulatory approved AI medical imaging application to perform diagnostics autonomously.
"ChestLink ushers in the era of AI autonomy in healthcare - something we have been promised by medical futurists and technology experts.…
Oxipit to offer free of charge retrospective CXR quality audit at RSNA
At the annual RSNA meeting, the AI medical imaging company will present the new ChestEye Quality AI double reading tool. To showcase vanguard ChestEye Quality capabilities, Oxipit will offer a free-of-charge quality audit for 6 months of retrospective CXR data. ChestEye Quality is already deployed in multiple medical institutions across Europe. With 229.617 images processed, the platform helped to identify 20% extra clinically relevant nodules, as well as numerous missed…
Teleradiología de Colombia partners with Oxipit for Chest X-Ray AI Diagnostics
Teleradiologia de Colombia – a leading diagnostic imaging services provider in Latin America – is rolling out Oxipit AI solutions across its network. Oxipit AI suite will produce preliminary chest X-Ray reports and identify healthy patient images with no abnormalities, augmenting radiologist productivity and improving radiologist workflow. It marks the first Oxipit deployment in Colombia with more announcements in Latin America coming soon.
Teleradiología de Colombia is the largest teleradiology services…
Oxipit Receives Patent for Improved AI Lung Cancer Diagnostics
Oxipit, creators of artificial intelligence based radiology imaging suite ChestEye, announces that the European Patent Office has approved their patent application. The innovation allows efficient use of high-resolution chest X-ray images for machine learning model training and is especially relevant for improving lung nodule detection.
Modern X-ray equipment produces large images with 16 Megapixel resolution being common. On the other hand, machine learning and artificial intelligence (AI) algorithms are typically optimized…
Oxipit ChestEye secures medical device certification in Australia
The AI medical imaging company has received an Australian Register of Therapeutic Goods Class IIa medical device certificate for ChestEye AI imaging service. Medical device certification paves the way for clinical use of ChestEye in the Australian market. ChestEye imaging suite is already certified by the CE mark. Oxipit received CE certification last February, enabling clinical ChestEye deployment in 32 European countries.
"Australia presents a very advanced, well developed healthcare landscape.…
